2017
Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHyperandrogenismHysterectomyMiddle AgedNeoadjuvant TherapyNeoplasm GradingOvarian NeoplasmsOvariectomyPostmenopauseRetrospective StudiesSalpingectomySertoli-Leydig Cell TumorConceptsSertoli-Leydig cell tumorOvarian Sertoli-Leydig cell tumorPresent patient populationDisease-free survivalSingle institution experienceTertiary care institutionTime of diagnosisOnset of menopauseRisk of recurrenceSeries of casesAdjuvant chemotherapyMedian followPostmenopausal bleedingPostmenopausal patientsMedian ageMedian intervalClinical presentationDefinitive managementPathological findingsRetrospective reviewInstitution experiencePatient populationTreatment modalitiesCell tumorsTumor grade
2015
Intravenous Leiomyomatosis Revisited
Carr RJ, Hui P, Buza N. Intravenous Leiomyomatosis Revisited. International Journal Of Gynecological Pathology 2015, 34: 169-176. PMID: 25675187, DOI: 10.1097/pgp.0000000000000127.Peer-Reviewed Original ResearchConceptsIntravenous leiomyomatosisSmooth muscle originMuscle originCases of IVLCommon extrauterine siteRight heart chambersGood overall prognosisPatients' medical recordsDirect mass effectGross pathologic findingsConventional diagnostic criteriaExtrauterine extensionExtrauterine involvementClinical sequelaeOverall prognosisDisease recurrenceMedian agePatient agePrompt diagnosisInitial diagnosisPathologic findingsSignificant morbiditySurgical excisionInferior venaPrimary lesion